Questions Regarding the Randomized Phase II Trial of Defactinib as Maintenance Therapy in Malignant Pleural Mesothelioma

J Clin Oncol. 2019 Sep 1;37(25):2293-2294. doi: 10.1200/JCO.19.00891. Epub 2019 Jul 22.

Authors

Ken Masuda¹, Hiroto Ishiki¹, Shunsuke Oyamada¹, Masaki Shimizu¹, Daisuke Kiuchi¹, Eriko Satomi¹

Affiliation

¹ Ken Masuda, MD and Hiroto Ishiki, MD, National Cancer Center Hospital, Tokyo, Japan; Shunsuke Oyamada, MS, JORTC Data Center, Tokyo, Japan; and Masaki Shimizu, MD; Daisuke Kiuchi, MD; and Eriko Satomi, MD, National Cancer Center Hospital, Tokyo, Japan.

PMID: 31329518
DOI: 10.1200/JCO.19.00891

No abstract available

Publication types

Comment

MeSH terms

Benzamides
Double-Blind Method
Humans
Mesothelioma*
Neurofibromin 2
Pleural Neoplasms*
Pyrazines
Sulfonamides

Substances

Benzamides
Neurofibromin 2
Pyrazines
Sulfonamides
defactinib